Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090080 | 0.86 | BACE1 (0.62) | CYP1A2KDM4EBACE1NFKBIARELA | |
| SCHEMBL12025134 | 0.82 | CYP1A2 (0.57) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL18438822 | 0.78 | BACE1 (0.47) | KDM4EBACE1PDE10AMETAP2PFKFB3 | |
| SCHEMBL29546 | 0.77 | NCF1 (0.50) | KDM4EBACE1PDE10AMETAP2PFKFB3 | |
| SCHEMBL30485659 | 0.76 | BACE1 (0.46) | KDM4EBACE1PDE10AMETAP2PFKFB3 | |
| SCHEMBL1721228 | 0.76 | BACE1 (0.50) | KDM4EBACE1PDE10AMETAP2PFKFB3 | |
| SCHEMBL30302548 | 0.76 | BACE1 (0.50) | KDM4EBACE1PDE10AMETAP2PFKFB3 | |
| SCHEMBL22573215 | 0.76 | BACE1 (0.46) | KDM4EBACE1PDE10AMETAP2PFKFB3 | |
| SCHEMBL22717988 | 0.76 | BACE1 (0.76) | KDM4EBACE1METAP2PFKFB3 | |
| SCHEMBL14661207 | 0.76 | KDM4E (0.55) | KDM4EBACE1PDE10AMETAP2PFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922845-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-06-20 | — | — | EP | disclosed |
| CN-103460086-B | Color composition for color filter and colour filter | TOYO INK SC HOLDINGS CO.,LTD. (JP) | 2016-05-18 | — | — | CN | disclosed |
| CN-103492377-B | As the triazolopyridine compounds of PIM kinase inhibitor | ARRAY BIOPHARMA INC. (US) | 2016-04-20 | — | — | CN | disclosed |
| US-9249102-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2678329-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-9073862-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-8889704-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-18 | — | — | US | disclosed |
| WO-2014081697-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2014-03-20 | — | — | US | disclosed |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053204-A1 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2009009633-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-0643045-B1 | Quinoline derivatives as leukotriene antagonists | NOVARTIS AG (CH) | 2000-03-08 | — | — | EP | disclosed |
| US-5508408-A | LEUKOTRIENE ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0643045-A1 | Quinoline derivatives as leukoriene antagonists | CIBA-GEIGY AG (CH) | 1995-03-15 | — | — | EP | disclosed |
| EP-0219308-B1 | 2-SUBSTITUTED QUINOLINES | MERCK FROSST CANADA INC. (CA) | 1991-10-23 | — | — | EP | disclosed |
| EP-0219308-A2 | 2-Substituted quinolines | MERCK FROSST CANADA INC. (CA) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNJ2 | CYP1A2 1298/4885KDM4E 367/4885BACE1 4047/4885 |
| US-20120053204-A1 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | CYP1A2 726/4885KDM4E 810/4885BACE1 3213/4885 |
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | CYP1A2 392/4885KDM4E 505/4885BACE1 3440/4885 |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | CYP1A2 392/4885KDM4E 505/4885BACE1 3440/4885 |
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | CYP1A2 6/4885KDM4E 539/4885BACE1 914/4885 |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | CYP1A2 69/4885KDM4E 326/4885BACE1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.